Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut
27/02/2026 17:53
Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' GENB.O shares fell 6.25% in its Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market volatility kept investors cautious toward new listings. (Reporting by Pragyan Kalita in Bengaluru; Editing by Sahal Muhammed) ((Pragyan.Kalita@thomsonreuters.com;))
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut